Tharimmune (THAR) Competitors

BioVie (NASDAQ:BIVI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Which has more volatility & risk, BIVI or THAR?

BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Is BIVI or THAR more profitable?

BioVie's return on equity of -100.88% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-100.88%	-78.49%
Tharimmune	N/A	-489.33%	-264.34%

Do insiders & institutionals hold more shares of BIVI or THAR?

4.6% of BioVie shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 2.4% of BioVie shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media favor BIVI or THAR?

In the previous week, BioVie had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.86 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Positive
Tharimmune	Neutral

Which has preferable valuation and earnings, BIVI or THAR?

Tharimmune is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$32.12M	-$79.10	-0.10
Tharimmune	N/A	N/A	-$12.20M	-$7.88	-0.23

Do analysts rate BIVI or THAR?

Tharimmune has a consensus target price of $17.00, suggesting a potential upside of 857.75%. Given Tharimmune's higher probable upside, analysts plainly believe Tharimmune is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Tharimmune	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Summary

BioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks.